We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 113

Snapshot of Sunshine rules in EU countries for the pharmaceutical industry part 1 - June 2014
  • McDermott Will & Emery
  • European Union, United Kingdom
  • June 12 2014

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. In 2013

Controlling and processing data in EU clinical trials
  • McDermott Will & Emery
  • European Union
  • November 22 2010

The legal regime for the conduct of clinical trials of medicinal products for human use in the European Union is set out in Directive 200120EC (the Clinical Trials Directive

Brexit Update: What’s Next for the Global Marketplace
  • McDermott Will & Emery
  • European Union, OECD, United Kingdom
  • June 28 2016

The United Kingdom’s vote to leave the European Union is expected to have complex legal implications for the United Kingdom, the European Union and

International news: focus on compliance - winter 2014
  • McDermott Will & Emery
  • China, European Union, Germany, Global, USA
  • December 2 2014

As regulatory oversight of companiesfrom Sarbanes Oxley and the Dodd-Frank Act to the Foreign Corrupt Practices Act (FCPA) and the UK Bribery

What did you say? $31 million awarded for infringement of hearing aid patent
  • McDermott Will & Emery
  • European Union
  • November 29 2012

In a case involving the alleged infringement of two patents related to hearing aids, one of which was found under judgment as a matter of law (JMOL) to not be infringed

CJEU Georgetown University SPC judgment
  • McDermott Will & Emery
  • European Union
  • January 22 2014

Following hot on the heels of the 14 November 2013 opinion given by the Advocate General in Georgetown University C-48412, the Court of Justice of

Increased European patent protection following a landmark ruling on supplementary protection certificates
  • McDermott Will & Emery
  • European Union
  • August 30 2012

The Court of Justice of the European Union (CJEU) rendered judgment relating to a preliminary reference from the English Court of Appeal, holding that the existence of an earlier marketing authorization (MA) of a pharmaceutical product does not preclude the grant of a Supplementary Protection Certificate (SPC) for a different application of the same product

GlaxoSmithKline infringed competition rules by restricting parallel trade
  • McDermott Will & Emery
  • European Union, Greece
  • April 4 2008

Advocate General Ruiz-Jarabo has delivered a non-binding opinion to the European Court of Justice (ECJ), finding that GlaxoSmithKline Plc (GSK) abused its dominant position by limiting distribution of certain pharmaceuticals to Greek wholesalers

EMEA and FDA focus on clinical research safety and enforcement
  • McDermott Will & Emery
  • European Union, USA
  • August 20 2009

Recent policy changes emphasize the need for sponsoring organizations to be even more vigilant in establishing, updating and monitoring their systems for compliance with clinical research requirements, whether conducted domestically or in a foreign locale

EPO Enlarged Board of Appeal invites the public to determine whether stem cells are contrary to morality
  • McDermott Will & Emery
  • European Union
  • July 30 2008

On 24 and 25 June 2008, in a public hearing on Wisconsin Alumni Research Foundation (WARF) Stem Cell patent application (G-0206), the European Patent Office (EPO) took the usual step of asking the public to assist it in making a determination regarding a patent application involving an invention in the controversial area of stem cell patenting